180-day efficacy of nirsevimab against hospitalisation for respiratory syncytial virus lower respiratory tract infections in infants (HARMONIE): a randomised, controlled, phase 3b trial

Authors

Institutions

Publication Details

Journal
The Lancet Child & Adolescent Health
Published
2025-05-14
DOI
https://doi.org/10.1016/s2352-4642(25)00102-6
Citations
36
Primary Topic
Respiratory viral infections research
Type
article
Field-Weighted Citation Impact
48.75

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

180-day efficacy of nirsevimab against hospitalisation for respiratory syncytial virus lower respiratory tract infections in infants (HARMONIE): a randomised, controlled, phase 3b trial

Karine Mari, Helen Hill, Simon B. Drysdale, M.N.P. Carreño et al.
36 citations
The Lancet Child & Adolescent Health
Respiratory viral infections research
48.75
article

180-day efficacy of nirsevimab against hospitalisation for respiratory syncytial virus lower respiratory tract infections in infants (HARMONIE): a randomised, controlled, phase 3b trial

Karine Mari, Helen Hill, Simon B. Drysdale, M.N.P. Carreño, Pierre Bourron, Florence Flamein, Markus Knuf, Natalya Vassilouthis, Simon Royal, Friedrich Kaiser, Andrea M. Collins, Alasdair Munro, Katrina Cathie, Michelle Roberts, Saul N. Faust, Didier Pinquier, Jonathan Cohen, Catherine Moreau, Pierre Tissières, Lydie Marcelon
article en
36 citations

Abstract

No abstract available for this paper.
The Lancet Child & Adolescent HealthVol. 9(6)
University of Nottingham (GB), Liverpool School of Tropical Medicine (GB), Sanofi (France) (FR), Hôpital Charles-Nicolle (FR), Klinik und Poliklinik für Kinder- und Jugendmedizin (DE), Sanofi (United States) (US), Praxis für Humangenetik (DE), Association Clinique et Thérapeutique Infantile du Val de Marne (FR), Sanofi (United Kingdom) (GB), Hôpital Intercommunal de Créteil (FR)
Pfizer, AstraZeneca, GlaxoSmithKline, Sanofi, European Society for Paediatric Infectious Diseases, Moderna, National Institute for Health and Care Research, Sanofi Pasteur
Good health and well-being
Openalex Percentile: Top 0%
Respiratory viral infections research
48.75
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.